Hydroxychloroquine for the treatment of severe respiratory infection by COVID-19: A randomized controlled trial.

ABSTRACT:

Introduction

The novel coronavirus pandemic (COVID-19) represents a major public health problem and it is key to find a treatment that reduces mortality. Our objective was to estimate whether treatment with 400 mg/day of Hydroxychloroquine for 10 days reduces in-hospital mortality in subjects with severe respiratory disease due to COVID-19 compared with placebo.

Material and methods

A double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of Hydroxychloroquine for the treatment of severe disease by COVID-19 through an intention-to-treat analysis. Eligible for the study were adults aged more than 18 years with COVID-19 confirmed by RT-PCR and lung injury requiring hospitalization with or without mechanical ventilation. Primary outcome was 30-da

SUBMITTER: Hernandez-Cardenas C 

PROVIDER: S-EPMC8478184 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature